- Home
- CAPR vs CLB Comparison
CAPR vs CLB Comparison
Compare CAPR & CLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- CLB
- Stock Information
- Founded
- CAPR 2005
- CLB 1936
- Country
- CAPR United States
- CLB United States
- Employees
- CAPR N/A
- CLB N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- CLB
- Sector
- CAPR Health Care
- CLB
- Exchange
- CAPR Nasdaq
- CLB Nasdaq
- Market Cap
- CAPR 600.7M
- CLB 717.9M
- IPO Year
- CAPR N/A
- CLB 1995
- Fundamental
- Price
- CAPR $9.72
- CLB $11.82
- Analyst Decision
- CAPR Strong Buy
- CLB Hold
- Analyst Count
- CAPR 8
- CLB 4
- Target Price
- CAPR $33.75
- CLB $15.00
- AVG Volume (30 Days)
- CAPR 3.3M
- CLB 519.2K
- Earning Date
- CAPR 08-06-2025
- CLB 07-23-2025
- Dividend Yield
- CAPR N/A
- CLB 0.35%
- EPS Growth
- CAPR N/A
- CLB N/A
- EPS
- CAPR N/A
- CLB 0.59
- Revenue
- CAPR $17,363,588.00
- CLB $517,796,000.00
- Revenue This Year
- CAPR $258.96
- CLB N/A
- Revenue Next Year
- CAPR $8.02
- CLB $2.92
- P/E Ratio
- CAPR N/A
- CLB $19.66
- Revenue Growth
- CAPR N/A
- CLB 1.32
- 52 Week Low
- CAPR $3.52
- CLB $10.15
- 52 Week High
- CAPR $23.40
- CLB $25.13
- Technical
- Relative Strength Index (RSI)
- CAPR 45.24
- CLB 45.30
- Support Level
- CAPR $6.07
- CLB $11.31
- Resistance Level
- CAPR $11.58
- CLB $11.98
- Average True Range (ATR)
- CAPR 1.59
- CLB 0.47
- MACD
- CAPR -0.23
- CLB -0.05
- Stochastic Oscillator
- CAPR 44.57
- CLB 6.32
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About CLB Core Laboratories Inc.
Core Laboratories Inc provides reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.